Literature DB >> 31563594

Novel BRCA2 pathogenic genotype and breast cancer phenotype discordance in monozygotic triplets.

Neslihan Duzkale1, Nilnur Eyerci2, Berna Oksuzoglu3, Taner Teker4, Olcay Kandemir5.   

Abstract

BRCA1/2 genes with high-penetrance are tumor suppressor and tumor susceptibility genes that play important roles in the homologous recombination mechanism in DNA repair and increase breast cancer risk. Variants in BRCA1 or BRCA2 are the main causes of familial and early-onset breast cancer. This study investigated pathogenic variant belonging to the BRCA2 gene splice region in monozygotic triplets. A 44-year-old woman was diagnosed with breast cancer when she was 32 years old. Her monozygotic sister had a history of breast cancer. No malignancy was detected in the third one of the monozygotic triplets. Sanger sequencing was used to evaluate the BRCA1/2 gene status of the patient and family members. It was figured out that they had the same genetic variant, a heterozygous germ-line splice region variant (c.7008-1G > C) in the BRCA2 gene. This novel splice region variant may be a new pathogenic variant of the BRCA2 gene. Its association with breast cancers needs to be further verified in more patient cases.
Copyright © 2019 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  A novel variant; BRCA; Breast cancer; Pathogenic

Year:  2019        PMID: 31563594     DOI: 10.1016/j.ejmg.2019.103771

Source DB:  PubMed          Journal:  Eur J Med Genet        ISSN: 1769-7212            Impact factor:   2.708


  2 in total

1.  The Relationship of Mutation Carriage of BRCA1/2 and Family History in Triple-Negative Breast Cancer: Experience from a Diagnostic Center in Turkey.

Authors:  Neslihan Duzkale; Olcay Kandemir
Journal:  Eur J Breast Health       Date:  2021-03-31

2.  Case Report: Next-Generation Sequencing-Based Detection in A Patient with Three Synchronous Primary Tumors.

Authors:  Tianqi Wu; Jian Wan; Kai Xia; Muqing Yang; Lijin Feng; Lu Yin; Chunqiu Chen
Journal:  Front Oncol       Date:  2022-07-15       Impact factor: 5.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.